21 completed, 6 recruiting, 2 active not recruiting, 2 terminated. 34 Phase 1, 19 Phase 2.
Follow Endothelial Dysfunction: new trials by email Literature Review of Endothelial Dysfunction trials Research Report on Endothelial Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of a Daily Supplement on Plasma PAI-1 Levels Supplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama - Aging, Endothelial Dysfunction | Phase 1 / Phase 2 | Active not recruiting | University of California, Los Angeles | 35 | 2026-02-24 | 2026-06-25 |
| TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD TB-500, Placebo - Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction | Phase 1 / Phase 2 | Recruiting | Hudson Biotech | 80 | 2026-02-05 | 2026-03-23 |
| Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis Imatinib, Compound sodium lactate solution - Sepsis, Fluid Overload | Phase 1 / Phase 2 | Unknown | Belfast Health and Social Care Trust | 65 | 2024-12-01 | 2024-10-04 |
| Fisetin to Improve Vascular Function in Older Adults Fisetin, Placebo - Aging, Endothelial Dysfunction | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Boulder | 70 | 2023-09-25 | 2026-09-25 |
| COMP-4 Supplementation and Brachial Artery FMD COMP-4 - Aging, Endothelial Dysfunction | Phase 1 / Phase 2 | Completed | University of California, Los Angeles | 32 | 2023-06-01 | 2026-03-09 |
| A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes C21 - Type2diabetes, Endothelial Dysfunction | Phase 1 | Completed | Vicore Pharma AB | 11 | 2023-03-31 | 2024-11-12 |
| Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep, Drug Lowering CBF and Intermittent Hypoxia Sleep, Placebo and Normoxia Sleep - Obstructive Sleep Apnea of Adult, Hypoxia, Brain | Phase 1 / Phase 2 | Recruiting | University of Calgary | 12 | 2023-01-01 | 2026-05-01 |
| Study to Assess Safety and Tolerability of Multiple Doses of EO2002 EO2002, Ripasudil - Corneal Edema, Corneal Endothelial Dystrophy | Phase 1 | Recruiting | Asociación para Evitar la Ceguera en México | 12 | 2022-11-08 | 2025-12-08 |
| B-Complex: A Nutraceutical SANS Countermeasure Vitamin B-Complex Supplement - Optic Disc Edema, Endothelial Dysfunction | Phase 1 | Recruiting | National Aeronautics and Space Administration (NASA) | 16 | 2022-08-01 | 2025-05-22 |
| MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution - Type 1 Diabetes, Diabetic Kidney Disease | Phase 1 | Recruiting | Kalie Tommerdahl | 60 | 2022-07-01 | 2025-06-13 |
| Isolation of Cells From Biopsy Tissue to Aid in Kidney Repair Cell isolation - Kidney Diseases, Endothelial Dysfunction | Phase 1 | Withdrawn | Brigham and Women's Hospital | 2022-01-21 | 2022-08-03 | |
| Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans Galantamine, Placebo, TENS 7000 - Endothelial Dysfunction | Phase 1 / Phase 2 | Recruiting | Vanderbilt University Medical Center | 160 | 2021-12-20 | 2026-05-18 |
| Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema EO2002, EO2002 low dose, EO2002 mid dose - Corneal Edema, Corneal Endothelial Dysfunction | Phase 1 | Completed | Emmecell | 42 | 2021-06-22 | 2025-03-05 |
| Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19) COVID-19 vaccine, Concentrate beetroot Juice, Nitrate-deplete beetroot juice - Cardiovascular Diseases, Endothelial Dysfunction | Phase 1 | Completed | Queen Mary University of London | 42 | 2021-05-10 | 2026-09-25 |
| A Phase 1/ Phase 2 Study of TTHX1114(NM141) TTHX1114(NM141), Vehicle (placebo) - Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy | Phase 1 / Phase 2 | Completed | Trefoil Therapeutics, Inc. | 22 | 2020-08-19 | 2023-10-30 |
| Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women Blueberry Powder, Placebo Powder - Hypertension, Aging | Phase 1 / Phase 2 | Completed | Colorado State University | 60 | 2020-01-01 | 2026-10-30 |
| Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial GSK2256294, Placebo - Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia | Phase 1 / Phase 2 | Completed | Oregon Health and Science University | 20 | 2018-05-02 | 2021-01-22 |
| Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression. UCMSCs, BMMSCs, Placebo - Endothelial Dysfunction, Metabolic Syndrome | Phase 1 / Phase 2 | Terminated | Joshua M Hare | 14 | 2018-04-12 | 2022-11-08 |
| Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function Charcoal hookah, E-coal hookah, Cigarette - Smoking, Endothelial Dysfunction | Phase 1 | Terminated | Cedars-Sinai Medical Center | 60 | 2017-08-15 | 2021-04-09 |
| Effects of Carbon Monoxide Breathing on Blood Vessel Function Carbon Monoxide - Endothelial Dysfunction | Phase 1 | Completed | Cedars-Sinai Medical Center | 9 | 2017-06-23 | 2019-04-01 |
Showing 20 of 34. Sign in to see all of them.
Cardiovascular Diseases (4) · Atherosclerosis (3) · Corneal Dystrophy, Posterior Polymorphous, 1 (3) · Fuchs' Endothelial Dystrophy (3) · Insulin Resistance (3) · Corneal Edema (2) · Coronary Artery Disease (2) · Hypertension (2) · COVID-19 (1) · Coitus (1) · Coronary Vasospasm (1) · Diabetes Mellitus, Type 1 (1) · Diabetic Nephropathies (1) · Edema (1) · Hypoxia, Brain (1)
Vascular Diseases (7) · Cardiovascular Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Nutritional and Metabolic Diseases (5) · Arterial Occlusive Diseases (4) · Arteriosclerosis (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Eye Diseases (4) · Genetic Diseases, Inborn (4) · Glucose Metabolism Disorders (4) · Hyperinsulinism (4) · Metabolic Diseases (4) · Pathologic Processes (4) · Behavior (3) · Corneal Diseases (3)
Acetylcysteine (1) · Ascorbic Acid (1) · COVID-19 Vaccines (1) · Carbon Monoxide (1) · Cell Separation (1) · Cerebrovascular Circulation (1) · Chocolate (1) · Cholecalciferol (1) · Citrulline (1) · Core Binding Factors (1) · Corn Oil (1) · Dental Occlusion (1) · Galantamine (1) · Imatinib Mesylate (1) · Injections (1)
Mayo Clinic (3) · Cedars-Sinai Medical Center (2) · University of California, Los Angeles (2) · Vanderbilt University Medical Center (2) · Asociación para Evitar la Ceguera en México (1) · Azienda Ospedaliera San Camillo Forlanini (1) · Belfast Health and Social Care Trust (1) · Brigham and Women's Hospital (1) · Colorado State University (1) · Emmecell (1) · Heinrich-Heine University, Duesseldorf (1) · Hospital Universitario Pedro Ernesto (1) · Hudson Biotech (1) · Indiana University (1) · Joshua M Hare (1)
United States (22) · Germany (2) · United Kingdom (2) · Canada (1) · China (1) · Italy (1) · Mexico (1) · Sweden (1)
Cyndya Shibao, MD (2) · Ronald Victor, MD (2) · Abdurrahman M Sweidan (1) · Amir Lerman, MD (1) · Joshua M Hare, MD (1) · Matthew J Rossman, PhD (1) · Mischie Nicolae Alexandru, MD (1) · Nazzaro Marco, MD (1) · Nicholas Leeper, MD (1) · Noelia Kunzevitzky (1) · Rajiv Gulati, MD (1) · Richard S Bruno, PhD, RD (1) · Ross Martini, MD (1) · Samir K Gupta, MD, MS (1) · Sara R Zwart, PhD (1)
PMID 23359371, PMID 24075893, PMID 25361769, PMID 25578927, PMID 25835348, PMID 26273791, PMID 26485680, PMID 27893465, PMID 30764644, PMID 32576603, PMID 33035428, PMID 34873674, PMID 37715222, PMID 37916745, PMID 39503770
2023 (1), K23HL159292 (1), R21DA041596 (1), UL1TR000135 (1)